Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 10/20 | 0.60 |
| ▸ | QDPR | P09417 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2803065 | 0.98 | HTR2C (0.61) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| Dimethylamine SCHEMBL9618528 | 0.94 | SLC18A3 (0.55) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL17850376 | 0.92 | SLC18A3 (0.53) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL14544196 | 0.87 | HTR3A (0.66) | SLC18A3SIGMAR1HTR2CHTR3A | |
| SCHEMBL15508750 | 0.87 | HTR3A (0.66) | SLC18A3SIGMAR1HTR2CHTR3A | |
| Toluene SCHEMBL27818685 | 0.85 | SLC18A3 (0.80) | SLC18A3SIGMAR1HTR2CKMT2A | |
| SCHEMBL1405569 | 0.83 | ESR2 (0.50) | SLC18A3HTR2C | |
| SCHEMBL4676148 | 0.81 | SLC18A3 (0.67) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL7966782 | 0.81 | HTR2C (0.64) | SLC18A3SIGMAR1HTR2CQDPR | |
| SCHEMBL10461059 | 0.79 | SLC18A3 (0.64) | SLC18A3SIGMAR1HTR2CQDPRHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2018-07-31 | — | — | US | claimed |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2017-08-31 | — | — | US | claimed |
| EP-3182971-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX Cardio, LLC (US) | 2017-06-28 | — | — | EP | claimed |
| WO-2016029037-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2016-02-25 | — | — | WO | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| EP-4067344-B1 | CYCLOALKYL UREA DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2025-11-26 | — | — | EP | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| CN-115003655-B | Cycloalkyl urea derivatives | 住友制药株式会社 | 2025-03-21 | — | — | CN | disclosed |
| US-20250066342-A1 | CYCLOALKYLUREA DERIVATIVE | Jazz Pharmaceuticals Therapeutics, Inc. | 2025-02-27 | — | — | US | disclosed |
| US-4871720-A | Aromatically substituted azacycloalkyl-alkanediphosphonic acids useful for the treatment of illnesses that can be attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0272208-A1 | Aromatically substituted azacyclo-alkylalkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-06-22 | — | — | EP | disclosed |
| US-4188396-A | ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1980-02-12 | — | — | US | disclosed |
| US-4110459-A | ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4101663-A | ANTIHYPERTENSIVES | AMERICAN HOECHST CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4086234-A | Process for the preparation of tertiary amines | G. D. SEARLE & CO. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4046900-A | TRANQUILIZERS, HYPOTENSIVES, ANALGESICS | AMERICAN HOECHST CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | SLC18A3 3852/4885SIGMAR1 480/4885HTR2C 716/4885 |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | SLC18A3 4361/4885SIGMAR1 3522/4885HTR2C 3890/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | SLC18A3 4364/4885SIGMAR1 4076/4885HTR2C 4530/4885 |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | SLC18A3 4361/4885SIGMAR1 3522/4885HTR2C 3890/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | SLC18A3 919/4885SIGMAR1 2679/4885HTR2C 235/4885 |
| US-20250066342-A1 | CYCLOALKYLUREA DERIVATIVE | HCRTR2, HCRTR1, CRHR2 | SLC18A3 376/4885SIGMAR1 107/4885HTR2C 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.